Date of filling in this questionnaire or last update: 22/05/2020
1. IDENTIFICATION & BASIC DESCRIPTION
Cohort name
  COBRA: Risk of COVID-19 in health care workers in Denmark
Country
 

  • Denmark

Name
  Henrik Kolstad
Institution
  Aarhus University Hospital
Email
  henkol@rm.dk
Phone
  4529610359
Name of committee
  Ethics approval not required in Denmark for a questionnaire-register linkage study as this
Contact Principal Investigator (name)
  Henrik Kolstad
Data access policy (briefly describe)
  Data will be uploaded with the National Health Data Authority and access to pseudonymized data will be possible through the principal investigator
Participation in pooled analyses
 

  • The cohort is potentially interested in participating in pooled analyses of (European) occupational cohort studies (note pooled analyses also includes remote decentralized analyses that would not require any transfer of primary data as well as meta-analyses).

Main aim of cohort, please briefly describe the main objectives of the cohort
  Analyze the risk of SARS-CoV-2 infection and COVID-19 disease in health care workers and the effect of protective equipment and procedures
Study design (please select as many as appropriate)
 

  • Prospective cohort

Source population (please select as many as appropriate)
 

  • Industry / occupation-based

Comparators (please select as many as appropriate)
 

  • Internal study population
  • External comparison of workers with other exposure

Inclusion criteria
  Employed April 2020 in hospitals in Central Denmark or Capitol Region of Denmark
Exclusion criteria
  None
Enrollment
  Ongoing
Age range at entry (main cohort)
 

Minimum Maximum Mean
18 70 40

Age range at entry (subcohort)
 

Minimum Maximum Mean Please describe
18 70 40

Men at enrollment
  4000
Women at enrollment
  16 000
Children (<18 years) at enrollment
  0
Men at last follow-up
  4000
Women at last follow-up
  16000
Children (<18 years) at last follow-up
  0
Participation rate at enrollment (if known)
  45
2. OUTCOME FOLLOW-UP
Type of data for outcome follow-up (please select as many as appropriate)
 

  • Active (contact with participants)
  • Disease incidence records
  • Use of registers (specify)
  • Other (specify)

Active (contact with participants) (specify)
 

  • Daily symptoms of respiratory infection

Disease incidence records (specify)
 

  • National patient register

Specify: Use of registers
 

  • National registers on hospital contacts, redeemed medications, members of the household

Specify: Other
 

  • Swab and serology on SARS-CoV-2 from ongoint surveillance program

First follow-up period (provide year)
  April 24, 2020
Last follow-up period (provide year)
  June 30, 2020
Number of follow-ups after baseline (provide number)
  68
Participation at last follow-up (if known)
  80
3. OCCUPATIONAL EXPOSURES
Source of exposure data collected (please select as many as appropriate)
 

  • Questionnaire, Personal (Self-reporting or interview)
  • Industry-based questionnaire
  • Job-employment records
  • Registry-based
  • Job calendar

Occupational history/time frame
  Current, at enrollment
Occupational coding performed
  Yes
Occupation (specify coding system used)
 

  • ISCO-08

Industry (specify coding system used)
 

  • NACE

Methods for exposure assessment (please select as many as appropriate)
 

  • Job Exposure Matrix
  • Self-report

 

  • Other

Specify: Job Exposure Matrix / Other
  COBRA-JEM will be developed for exposure characterization of non-responders
Main categories
 

  • Biological factors

Biological factors | Viruses
 

  • Other (specify)

Biological factors | Viruses | Specify: Other
  SARS-CoV-2
4. OUTCOMES EVALUATED
Baseline - type of outcome data collected (select more than one if applicable)
 

  • Biomarker (specify)
  • Questionnaire, individual (self-recording or interview)

Specify: Biomarker
  SARS-CoV-2 PCR and Ab
Follow-up - type of outcome data collected (select more than one if applicable)
 

  • Biomarker (specify)
  • Questionnaire, individual (self-recording or interview)

Specify: Biomarker
  SARS-CoV-2 PCR and Ab
Outcome type (please select as many as appropriate)
 

  • Morbidity

Diagnostic groups based on ICD10
 

  • B Viral infections, type of microorganisms*

B Viral infections, type of microorganisms
 

  • SARS coronavirus

5. BIOLOGICAL SAMPLES & ANALYSIS
Biological samples collected
 

  • Blood

6. Other Information
 

  • Anthropometry
  • Education
  • Smoking
  • Other (specify)

Specify: Other
  PPE
Possibility for linkage to data registries/data enrichment via data linkage
 

  • Cancer incidence
  • Disease specific clinical database
  • Employment status
  • Hospital discharge
  • Medication usage
  • Migration
  • Mortality register
  • Other (specify)

Specify: Other
  House hold members